MicroRNAs in testicular cancer: Implications for pathogenesis, diagnosis, prognosis and therapy

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2709-2714

  Bezan, Angelika ^a   Gerger, Armin ^a   Pichler, Martin ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Diagnosis; microRNAs; Pathophysiology; Prognosis; Review; Testicular cancer

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE; MICRORNA; MICRORNA 105; MICRORNA 106A; MICRORNA 196; MICRORNA 199A; MICRORNA 217; MICRORNA 221; MICRORNA 222; MICRORNA 293; MICRORNA 302; MICRORNA 30A; MICRORNA 34A; MICRORNA 371; MICRORNA 372; MICRORNA 373; MICRORNA 383; MICRORNA 99; UNCLASSIFIED DRUG; TUMOR MARKER;

ALPHA FETOPROTEIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CARCINOMA; CHORIOCARCINOMA; CLINICAL PRACTICE; DEVELOPED COUNTRY; EMBRYONAL CARCINOMA; GONADOTROPIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE INFERTILITY; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; TESTIS CANCER; TESTIS TERATOMA; YOLK SAC TUMOR; BLOOD; DIAGNOSIS; GENETICS; MALE; PATHOPHYSIOLOGY; PROGNOSIS; TESTIS TUMOR;

DIAGNOSIS; MICRORNAS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TESTICULAR CANCER;

HUMANS; MALE; MICRORNAS; PROGNOSIS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906318597     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Al-Ali BM, Ress AL, Gerger A and Pichler M: MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 32: 3727-3732, 2012.
2. Ambros V: microRNAs: tiny regulators with great potential. Cell 107: 823-826, 2001.
3. Bach D, Fuereder J, Karbiener M, Scheideler M, Ress AL, Neureiter D, Kemmerling R, Dietze O, Wiederstein M, Berr F, Plaetzer K, Kiesslich T and Pichler M: Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment. Journal of photochemistry and photobiology B, Biology 120: 74-81, 2013.
4. Belge G, Dieckmann KP, Spiekermann M, Balks T and Bullerdiek J: Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors? European Urol 61: 1068-1069, 2012.
5. Bing Z, Master SR, Tobias JW, Baldwin DA, Xu XW and Tomaszewski JE: MicroRNA expression profiles of seminoma from paraffin-embedded formalin-fixed tissue. Virchows Archiv: an international J Pathol 461: 663-668, 2012.
6. Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM and Chan WY: Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene 30: 3404-3415, 2011.
7. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK and Calin GA: MicroRNAs in body fluids-the mix of hormones and biomarkers. Nature Reviews Clinical Oncol 8: 467-477, 2011.
8. Dieckmann KP, Spiekermann M, Balks T, Flor I, Loning T, Bullerdiek J and Belge G: MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. British journal of cancer 107: 1754-1760, 2012.
9. Duale N, Lindeman B, Komada M, Olsen AK, Andreassen A, Soderlund EJ and Brunborg G: Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Molecular cancer 6: 53, 2007.
10. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
11. Gillis AJ, Rijlaarsdam MA, Eini R, Dorssers LC, Biermann K, Murray MJ, Nicholson JC, Coleman N, Dieckmann KP, Belge G, Bullerdiek J, Xu T, Bernard N and Looijenga LH: Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Molecular Oncol 7: 1083-1092, 2013.
12. Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW, Sun Y, Chen C, Guenther S, Sherlock J, Veltman I, Baeten J, van der Spek PJ, de Alarcon P and Looijenga LH: High-throughput microRNAome analysis in human germ cell tumours. J Pathol 213: 319-328, 2007.
13. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Hofler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB and Speicher MR: Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. International journal of cancer Journal international du cancer 133: 346-356, 2013.
14. Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, Benezeder T, Auer M, Pischler C, Mannweiler S, Pichler M, Eisner F, Haeusler M, Riethdorf S, Pantel K, Samonigg H, Hoefler G, Augustin H, Geigl JB and Speicher MR: Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5: 30, 2013.
15. Horwich A, Shipley J and Huddart R: Testicular germ-cell cancer. Lancet 367: 754-765, 2006.
16. Jung YH, Gupta MK, Shin JY, Uhm SJ, and Lee HT: MicroRNA signature in testes-derived male germ-line stem cells. Mol Human Reproduction 16: 804-810, 2010.
17. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA and de Jong S: Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clinical Investigation 120: 3594-3605, 2010.
18. Lian J, Tian H, Liu L, Zhang XS, Li WQ, Deng YM, Yao GD, Yin MM and Sun F: Down-regulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death & Disease 1: e94, 2010.
19. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews Drug Discovery 12: 847-865, 2013.
20. Liu L, Lian J, Zhang H, Tian H, Liang M, Yin M and Sun F: MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J Cellular Physiology 228: 2294-2304, 2013.
21. Lize M, Pilarski S and Dobbelstein M: E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differentiation 17: 452-458, 2010.
22. Looijenga LH, Gillis AJ, Stoop H, Hersmus R and Oosterhuis JW: Relevance of microRNAs in normal and malignant development, including human testicular germ cell tumours. International J Andrology 30: 304-314; discussion 314-305, 2007.
23. McIver SC, Roman SD, Nixon B and McLaughlin EA: miRNA and mammalian male germ cells. Human Reproduction Update 18: 44-59, 2012.
24. McIver SC, Stanger SJ, Santarelli DM, Roman SD, Nixon B and McLaughlin EA: A unique combination of male germ cell miRNAs coordinates gonocyte differentiation. PloS one 7: e35553, 2012.
25. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Nat Acad Sciences USA 105: 10513-10518, 2008.
26. Murray MJ and Coleman N: Testicular cancer: a new generation of biomarkers for malignant germ cell tumours. Nature Reviews Urol 9: 298-300, 2012.
27. Novotny GW, Belling KC, Bramsen JB, Nielsen JE, Bork-Jensen J, Almstrup K, Sonne SB, Kjems J, Rajpert-De Meyts E and Leffers H: MicroRNA expression profiling of carcinoma in situ cells of the testis. Endocrine-related Cancer 19: 365-379, 2012.
28. Novotny GW, Nielsen JE, Sonne SB, Skakkebaek NE, Rajpert-De Meyts E, and Leffers H: Analysis of gene expression in normal and neoplastic human testis: new roles of RNA. International J Andrology 30: 316-326; discussion 326-317, 2007.
29. Palmer RD, Murray MJ, Saini HK, van Dongen S, Abreu-Goodger C, Muralidhar B, Pett MR, Thornton CM, Nicholson JC, Enright AJ and Coleman N: Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res 70: 2911-2923, 2010.
30. Pichler M, Ress AL, Winter E, Stiegelbauer V, Karbiener M, Schwarzenbacher D, Scheideler M, Ivan C, Jahn SW, Kiesslich T, Gerger A, Bauernhofer T, Calin GA and Hoefler G: MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. British J Cancer 110: 1614-1621, 2014.
31. Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, Lax S, Samonigg H and Hoefler G: miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clinical Pathol 2013.
32. Pichler M, Winter E, Stotz M, Eberhard K, Samonigg H, Lax S and Hoefler G: Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. British J Cancer 106: 1826-1832, 2012.
33. Schwarzenbacher D, Balic M and Pichler M: The role of microRNAs in breast cancer stem cells. Intern J Mol Sciences 14: 14712-14723, 2013.
34. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA and Croce CM: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. The lancet Oncol 11: 136-146, 2010.
35. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH and Agami R: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Advances in Experimental Medicine Biol 604: 17-46, 2007.
36. Walsh TJ, Croughan MS, Schembri M, Chan JM and Turek PJ: Increased risk of testicular germ cell cancer among infertile men. Archives of Internal Med 169: 351-356, 2009.
37. Wittmann J and Jack HM: Serum microRNAs as powerful cancer biomarkers. Biochimica et biophysica acta 1806: 200-207, 2010.